Latest News From Lumira Ventures

Endotronix Joins American Heart Association’s Center for Health Technology & Innovation to Broaden the Use of Guideline-Based Care for Heart Failure Patients

Ahmed Khan Portfolio News

LISLE, Ill., June 28, 2018 /PRNewswire/ — Endotronix, Inc., a digital health, medtech company dedicated to advancing the treatment of heart failure, today announced they have joined the American Heart Association’s Center for Health Technology & Innovation’s (CHTI) Innovators Network. The collaboration allows Endotronix …

Zymeworks Closes Previously Announced Public Offering

Ahmed Khan Portfolio News

VANCOUVER, British Columbia–(BUSINESS WIRE)–Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics, announced today that it has closed its previously announced underwritten public offering (the “Offering”) of 6,210,000 common shares, including …

Opsens Applauds Japanese Government New Regulation Supporting Diagnosis, Such as FFR, Before Treatment of Coronary Stenosis

Ahmed Khan Portfolio News

Quebec City, Quebec, April 24, 2018 – Opsens Inc. (“Opsens” or the “Company”) (TSX:OPS)(OTCQX:OPSSF) applauds Japan’s Ministry of Health, Labor and Welfare (“MHLW”) on its new regulation requiring the evaluation of any coronary stenosis prior to its treatment, specifically mentioning Fractional Flow Reserve (“FFR”) as …

Zymeworks and Celgene Expand Bispecific Antibody Collaboration

Ahmed Khan Portfolio News

VANCOUVER, British Columbia–(BUSINESS WIRE)–Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced that Celgene Corporation has exercised its right to expand its collaboration agreement for the research, development, and commercialization of bispecific antibody therapeutics using Zymeworks’ …